Biohaven Ltd. (BHVN)
NYSE: BHVN · Real-Time Price · USD
12.18
+0.25 (2.10%)
Oct 9, 2026, 2:27 PM EDT - Market open
Biohaven Employees
Biohaven had 274 employees as of December 31, 2025. The number of employees increased by 18 or 7.03% compared to the previous year. That makes Biohaven the 24,541st largest employer in the world and 3,152nd in the United States.
Employees
274
Change (1Y)
18
Growth (1Y)
7.03%
Revenue / Employee
n/a
Profits / Employee
-$2,141,755
Market Cap
1.84B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 274 | 18 | 7.03% |
| Dec 31, 2024 | 256 | 17 | 7.11% |
| Dec 31, 2023 | 239 | 37 | 18.32% |
| Dec 31, 2022 | 202 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Sarepta Therapeutics | 835 |
| Novavax | 749 |
| Agios Pharmaceuticals | 540 |
| Xencor | 260 |
| Zymeworks | 231 |
| Zenas BioPharma | 167 |
| Absci | 140 |
| Mesoblast | 108 |
BHVN News
- 1 day ago - Biohaven enters strategic licensing, collaboration pact with Ono Pharmaceutical - TheFly
- 1 day ago - Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease - PRNewsWire
- 11 days ago - Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026 - PRNewsWire
- 21 days ago - Citi views Xenon study pause as positive for Biohaven - TheFly
- 27 days ago - Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) - PRNewsWire
- 4 weeks ago - Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow. - Barrons
- 4 weeks ago - Biohaven clinical hold adds level of uncertainty, says H.C. Wainwright - TheFly
- 4 weeks ago - Biohaven falls -14.0% - TheFly